Home About AIPPI Committees Pharma

Pharma

The AIPPI Pharma Committee monitors, comments and advises AIPPI on policy, regulatory and legal frameworks relating to intellectual property protection for pharmaceutical products and processes, diagnostic products and medical devices. The Committee also considers policy initiatives, and best practices for national and regional legislation.

Position paper on the waiver for certain provisions of the TRIPS agreement for the prevention, containment and treatment of COVID-19 proposed by some countries within the WTO.

Terms of Reference.

Standing Committee

Pharma

Status: Active

Committee Leadership

Charles Aaron BOULAKIA (CA) (Vice Chair)

Martin KLOK (NL) (Vice Chair)

John C. TODARO (US ) (Chair)

Committee Members

Hameeda ASIF (PK)

Ezgi BAKLACI GÜLKOKAR (TR)

Martín BENSADON (AR)

Cristina BIGGI (IT)

Anna BLADH REDZIC (SE)

Mariangela BOGNI (IT)

Brigitte CARION TARAVELLA (FR)

Héctor E. CHAGOYA C. (MX)

I. Soley COBAN (TR)

Magali CONTARDI (IT)

Magnus DAHLMAN (SE)

Li FENG (US)

Kevin CW FENG (TW)

Amy FENG (CN)